



Recombinant Vaccine for Human and Animal Diseases

Guest Editor:

Dr. Shawn Babiuk

National Centre for Foreign
Animal Disease, Canadian Food
Inspection Agency, Winnipeg, MB
R3E 3M4, Canada

Deadline for manuscript
submissions:

30 April 2025

Message from the Guest Editor

Dear Colleagues,

Vaccination has proven to be the most cost-effective strategy for controlling infectious diseases in humans and animals. Vaccines effectively control newly emerging and re-emerging pathogens. Various protein expression platforms are available to meet different vaccine needs. Research and development of these platforms is driven mainly by the production of vaccine antigens for subunit vaccine research. This Special Issue will focus on recombinant subunit antigen vaccines produced using different protein expression systems, including bacterial, insect, mammalian, and yeast. The aim is to develop vaccines to prevent diseases in humans and animals. This Special Issue is open to research articles, reviews, and brief reports on recombinant vaccines.

We look forward to receiving your contributions.

Dr. Shawn Babiuk

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com